Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

EyeTREAT

Financiado

Cerrado

Innovative tool for personalized treatment of patients with neovascular age macu...

Innovative tool for personalized treatment of patients with neovascular age macular degeneration dosage optimization for long term efficacy treatment With the ageing population, visual threatening illnesses are increasing. For instance, age-related macular degeneration (AMD) is expected to affect almost 25 million Europeans by 2040. The AMD treatment consists in regular injecti... ver más

30/11/2019

UNIVERSITY OF MANC...

122K€

Presupuesto del proyecto: 122K€

Líder del proyecto

THE UNIVERSITY OF MANCHESTER No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-11-30

MSCA-IF-2017: Individual Fellowships

I+D

Cerrada hace 7 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

UNIVERSITY OF MANCHESTER

122.16K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PID2021-124400OA-I00 IDENTIFICACION DE DIANAS TERAPEUTICAS DERIVADAS DE LOS PERIC... 169K€ Cerrado

TED2021-131913B-I00 TECNICAS DE DEEP LEARNING E INTERPRETACION DE INTELIGENCIA A... 239K€ Cerrado

NeoVasculoStop NATURAL INTRAOCULAR PHOTOACTIVATION OF COMPOUNDS TO FIGHT RE... 3M€ Cerrado

EYE-RISK Exploring the combined role of genetic and non genetic facto... 6M€ Cerrado

BES-2017-080518 DESARROLLO DE METODOLOGIAS BASADAS EN ESPECTROMETRIA DE MASA... 93K€ Cerrado

I-SEE Cell Rejuvenation Therapy for Age-related Macular Degenerati... 150K€ Cerrado

Duración del proyecto: 20 meses Fecha Inicio: 2018-03-07
Fecha Fin: 2019-11-30

Líder del proyecto

THE UNIVERSITY OF MANCHESTER No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 122K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto With the ageing population, visual threatening illnesses are increasing. For instance, age-related macular degeneration (AMD) is expected to affect almost 25 million Europeans by 2040. The AMD treatment consists in regular injections of the anti-VEGF therapeutic drug (Lucentis, Avastin, Eylea) into the eye ball, vitreous, for the rest of the patient life. However, the dosing intervals varies widely among the patients and there is no a clear consensus or quantitative method for evaluating the injection frequency. For that, computational tools linking the drug dose regimen and the drug effect in the retina are needed. However, such pharmacokinetic-pharmacodynamic models are still missing. Combining population pharmacokinetic and optical coherence tomography (OCT) imaging technique is a new, novel and promising approach. The drug effect can be evaluated non-invasively, measuring the central macular thickness in the retina scan. The models generated will allow appropriate individualized dosing regimen to the patients in clinics that will be anticipated from individual retina scan determinations with OCT. The optimization and personalization of dosing regimen will ensure an efficient long-lasting treatment, improving patient quality of life while reducing the burden to the health care system. Moreover, the models will increase our understanding in the treatments, constitute a pioneer tool in effect assessment in ocular therapeutic field and a first step towards more advanced ophthalmic models. The candidate has strong expertise in intravitreal pharmacokinetic and this project will advance her into clinical pharmacodynamic modelling at the renowned Centre for Applied Pharmacokinetic Research, University of Manchester. The inter-disciplinary and inter-sectoral character of the project will definitely benefit her career development as a researcher.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores